{"id":"trc150094","safety":{"commonSideEffects":[{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PPARδ agonists activate the delta isoform of peroxisome proliferator-activated receptors, which regulate genes involved in fatty acid oxidation and glucose homeostasis. TRC150094 is designed to improve metabolic parameters in insulin-resistant conditions by promoting lipid utilization and reducing hepatic glucose production, with a favorable safety profile compared to earlier PPAR agonists.","oneSentence":"TRC150094 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that enhances insulin sensitivity and lipid metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:57.355Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Non-alcoholic fatty liver disease (NAFLD)"}]},"trialDetails":[{"nctId":"NCT03254446","phase":"PHASE3","title":"Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension","status":"UNKNOWN","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2018-03-12","conditions":"Diabetes, Dyslipidemias, Hypertension","enrollment":1250},{"nctId":"NCT01408667","phase":"PHASE1, PHASE2","title":"Hyperinsulinemic Euglycemic Clamp Protocol","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2011-11","conditions":"Metabolic Cardiovascular Syndrome","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TRC150094","genericName":"TRC150094","companyName":"Torrent Pharmaceuticals Limited","companyId":"torrent-pharmaceuticals-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TRC150094 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that enhances insulin sensitivity and lipid metabolism. Used for Type 2 diabetes mellitus, Non-alcoholic fatty liver disease (NAFLD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}